Meiji Seika Pharma Co. Ltd.
- Address
- 4-16 Kyobashi 2-chome Chuo-ku
Sponsor Overview
Specializations
Antibacterial Therapy for Resistant Gram-Negative Infections
Meiji Seika Pharma Co. Ltd. focuses on antibacterial therapy for serious infections caused by carbapenem-resistant Enterobacterales, with research centered on treatment options for difficult-to-manage bacterial disease.
- Complicated urinary tract infection (cUTI)
- Acute uncomplicated pyelonephritis (AP)
- Carbapenem-resistant Enterobacterales (CRE)
The sponsor’s research activity includes clinical evaluation of combination antibacterial approaches in adult patients with resistant infections affecting the urinary tract and related systemic bacterial disease.
Hospital-Acquired and Ventilator-Associated Pneumonia
Another area of interest is hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, reflecting attention to severe lower respiratory tract infections in hospitalized adults.
- Hospital-acquired bacterial pneumonia (HABP)
- Ventilator-associated bacterial pneumonia (VABP)
These studies align with treatment needs in intensive care and inpatient settings where resistant pathogens and limited therapeutic options are major clinical concerns.
Complicated Intra-Abdominal Infection
The sponsor also supports research in complicated intra-abdominal infection, a major bacterial infection category requiring broad-spectrum treatment coverage and careful clinical management.
- Complicated intra-abdominal infection (cIAI)
- Adult infectious disease treatment
This area extends the sponsor’s antibacterial portfolio into severe abdominal infections associated with significant clinical complexity and resistant organisms.
Intravenous Anti-Infective Treatment Development
Meiji Seika Pharma Co. Ltd. is engaged in intravenous anti-infective research involving cefepime/nacubactam and aztreonam/nacubactam, with interest in treatment options for adults across multiple serious bacterial infections.
- Cefepime/nacubactam
- Aztreonam/nacubactam
- Imipenem/cilastatin
The clinical focus includes efficacy and safety assessment in infection settings where resistant pathogens complicate standard care.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam in Adults with CRE-Related Complicated Infections |  Croatia Czechia France Greece Latvia Slovakia Spain | Not Recruiting |
| Phase 3 Randomized Double-Blind Study of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Imipenem/Cilastatin in Complicated UTI and Acute Pyelonephritis |  Bulgaria Czechia Estonia Latvia Lithuania Slovakia | Not Recruiting |
Data & Insights
This sponsor works with 10 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 36 sites across their trial portfolio.
Therapeutic Focus
- 1.Bacterial Infections and Mycoses2 trials180 other sponsors
Partnered Research Centres
36 centres- Address
- Bulevard Nikola Yonkov Vaptsarov 51b, 1407 Sofia
- Address
- Mudr. Pribulu 412/4, 089 01 Svidník
- Address
- 2 Avenue Martin Luther King, 87000 Limoges
- Address
- 4 Place Du Professeur Robert Debre, Bp 40026, 30029 Nîmes
- Address
- Viestura Iela 5, 5401 Daugavpils
- Address
- Triaditsa, Ulitsa Sveti Georgi Sofiyski 1, 1431 Sofia
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Meiji Seika Pharma Co. Ltd..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.